Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes

被引：0
|
作者：
Herbst, Roy S. [1 ]
Stern, Howard [2 ]
Amler, Lukas [2 ]
Otterson, Gregory [3 ]
Lin, Ming [2 ]
O'Connor, Paula [2 ]
Hainsworth, John [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Sarah Cannon Rsrch Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [21] Population-based evaluation of second-line palliative chemotherapy (SCT) versus erlotinib (E) in advanced non-small cell lung cancer (NSCLC) patients (pts).
    Noonan, Krista
    Ho, Cheryl
    Sun, Sophie
    Melosky, Barbara L.
    Laskin, Janessa J.
    Murray, Nevin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials
    Thatcher, Nick
    Lynch, Thomas J.
    Butts, Charles
    Rosell, Rafael
    Shepherd, Frances
    Pujol, Jean-Louis
    Vansteenkiste, Johan
    Emig, Michael
    Groos, Jutta
    Pirker, Robert
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S297 - S297
  • [24] Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
    Wakelee, Heather A.
    Dahlberg, Suzanne E.
    Keller, Steven M.
    Tester, William J.
    Gandara, David R.
    Graziano, Stephen L.
    Adjei, Alex
    Leighl, Natasha
    Aisner, Seena C.
    Rothman, Jan M.
    Patel, Jyoti
    Sborov, Mark D.
    Mcdermott, Sean R.
    Perez-Soler, Roman
    Traynor, Anne M.
    Butts, Charles
    Evans, Tracey
    Horn, Leora
    Ramalingam, Suresh S.
    Schiller, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S796 - S796
  • [25] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Wozniak, A. J.
    Kalemkerian, G. P.
    Gadgeel, S. M.
    Schneider, B. J.
    Valdivieso, M.
    Venkatramanamoorthy, R.
    Hackstock, D. M.
    Chen, W.
    Heilbrun, L. K.
    Ruckdeschel, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A PHASE II TRIAL OF PEMETREXED (P), GEMCITABINE (G), AND BEVACIZUMAB (BV) IN UNTREATED PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Wozniak, Antoinette
    Kalemkerian, Gregory
    Gadgeel, Shirish M.
    Ramnath, Nithya
    Schneider, Bryan
    Valdivieso, Manuel
    Smith, Daryn
    Hackstock, Deborah
    Chen, Wei
    Ruckdeschel, John
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1234 - S1235
  • [28] A phase II trial of pemetrexed (P), gemcitabine (G), and bevacizumab (BV) in untreated patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Wozniak, Antoinette J.
    Kalemkerian, Gregory P.
    Gadgeel, Shirish M.
    Schneider, Bryan J.
    Valdivieso, Manuel
    Smith, Daryn
    Hackstock, Deborah M.
    Chen Wei
    Heilbrun, Lance K.
    Ruckdeschel, John D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S454 - S454
  • [29] A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC)
    Puiol, J.
    Lynch, T. J.
    Rosell, R.
    Butts, C. A.
    Shepherd, F. A.
    Thatcher, N.
    Vansteenkiste, J.
    Manegold, C.
    Groos, J.
    Pirker, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 508 - 508
  • [30] OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY
    Boyer, Michael
    Blackhall, Fiona H.
    Barrios, Carlos H.
    Frank, Richard C.
    Heo, Deo Seog
    Park, Keunchil
    Rosell, Rafael
    Talbot, Denis C.
    Taylor, Ian C.
    Liang, Jane
    Campbell, Alicyn K.
    O'Connell, Joseph
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S318 - S319
12345